Skip to the reading

[Peptide Studies](/)

[Study leaves](/tirzepatide) [The sources](/references) [Our approach](/about)

We read peptide research one study at a time, keeping what happened beside what remains unshown.

- [Peptide Studies](/)
- PT-141

# The PT-141 trials asked about desire and the distress around it.

These trials looked at low sexual desire and the distress it caused. We want to understand that result without asking it to explain every part of someone's sex life or relationship.

06

## What the women in the trials reported

![An anonymous adult woman seated at the edge of a shared bed, with her clothed partner quietly farther back.](/study-leaves-3d0d256cd049/pt141-closeness.webp)

A private pause brings us to the subject of intimacy, without telling us how either person feels. The people pictured aren't trial participants; the account follows the women's own reports.

PT-141 is another name for bremelanotide. The [two trials reported together](https://pubmed.ncbi.nlm.nih.gov/31599840/) studied women who hadn't reached menopause and had hypoactive sexual desire disorder. That means low sexual desire that causes distress; we'll leave the long name there.

The trials compared bremelanotide with a placebo, a dummy treatment, for 24 weeks. Chance determined which treatment each woman received. Researchers measured changes in desire and in the distress linked to low desire.

Women receiving bremelanotide improved more on those measures than women receiving placebo. That's evidence of an effect in the groups studied. It doesn't tell us how much any one woman's everyday experience changed.

We find the two parts of the question useful. Desire is one thing; how someone feels about low desire is another. Keeping both in view gives us a clearer account than a sweeping claim about better sex.

Nausea, flushing and headache were common side effects. The [prescribing information also warns about a temporary rise in blood pressure](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9). It rules out use in people with uncontrolled high blood pressure or known heart and blood-vessel disease.

The approved medicine is a prescription injection of bremelanotide. The label specifies acquired and generalized HSDD and limits the use to women before menopause. Acquired means this wasn't always a problem; generalized means it occurs across situations, rather than with just one partner. PT-141 research chemicals are outside that approval. It also excludes use in men, after menopause or for general sexual enhancement.

For someone wondering whether the result relates to their own life, a licensed U.S. clinician can assess the problem and discuss approved treatment where appropriate. The paper gives us something specific to talk about. It can't diagnose the reader.

That is where the question passes from a paper to an individual assessment. At Promise Peptides (mypromise.com), a licensed clinician reviews a woman's health before prescribing compounded PT-141, which is not FDA-approved; care is limited to U.S. patients; some patients are declined.

### What this did not show

These trials don't establish a benefit for everyone with low desire. They studied a defined group and measured particular changes over 24 weeks. Improvements in desire and distress don't prove a repaired relationship or better sexual performance for everyone.

We'd keep the result in those everyday words: desire improved and related distress eased more than with placebo. That's worth understanding on its own. It doesn't need to become a promise about the rest of someone's intimate life.

[Return to the human and animal accounts](/)

[Opening accounts](/#study-accounts) [Retatrutide](/retatrutide) [Tesamorelin](/tesamorelin) [PT-141](/pt-141) [References](/references) [About](/about) [Contact](/contact)

Peptide Studies is a place to read a paper carefully—a guide to the research, never a clinic, pharmacy or seller.

© 2026 Peptide Studies